Cargando…

Individualizing medical treatment of overactive bladder

Overactive bladder (OAB) syndrome is highly prevalent in both men and women and might have negative impact on quality of life. Clinical trials of OAB usually highly select participants that may not reflect the real-world practice of OAB patients. The spectrum of OAB includes patients with idiopathic...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172903/ https://www.ncbi.nlm.nih.gov/pubmed/30305780 http://dx.doi.org/10.4103/tcmj.tcmj_83_18

Ejemplares similares

Practical points in the medical treatment of overactive bladder and nocturia in the elderly
por: Chen, Jing-Liang, et al.
Publicado: (2016)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies
por: Kuo, Hann-Chorng
Publicado: (2020)

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A
por: Wang, Chung-Cheng, et al.
Publicado: (2020)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?
por: Ke, Qian-Sheng, et al.
Publicado: (2020)

Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice
por: Wang, Hsiu-Jen, et al.
Publicado: (2021)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?
por: Chuang, Fei-Chi, et al.
Publicado: (2018)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
por: Liu, Hsin-Tzu, et al.
Publicado: (2013)

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
por: Hsiao, Sheng-Mou, et al.
Publicado: (2015)

Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder
por: Hsiao, Sheng-Mou, et al.
Publicado: (2017)

Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome
por: Liu, Hsin-Tzu, et al.
Publicado: (2015)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Overactive bladder: the importance of tailoring treatment to the individual patient
por: Drutz, Harold P
Publicado: (2011)

Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders
por: Hung, Fan-Ching, et al.
Publicado: (2022)

Persistence and compliance with medication management in the treatment of overactive bladder
por: Kim, Tae Heon, et al.
Publicado: (2016)

Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2015)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Urinary Oxidative Stress Biomarkers in the Diagnosis of Detrusor Overactivity in Female Patients with Stress Urinary Incontinence
por: Chen, Wei-Hsin, et al.
Publicado: (2023)

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
por: Lin, Chih-Chieh, et al.
Publicado: (2023)

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
por: Ou, Yin-Chien, et al.
Publicado: (2023)

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Current pharmacological and surgical treatment of underactive bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2017)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Medical management of overactive bladder
por: Ubee, Sarvpreet S., et al.
Publicado: (2010)

Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery
por: Lee, Hsiang-Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rcerrke6k01r6je6h8l3tabhuv